Amarin down as topline contracts in Q4
Source: SeekingAlpha
2026-02-25 10:17:23 ET
More on Amarin
- Amarin expects full-year 2025 revenue in-line with estimates
- Seeking Alpha’s Quant Rating on Amarin
- Historical earnings data for Amarin
- Financial information for Amarin
Read the full article on Seeking Alpha
For further details see:
Amarin down as topline contracts in Q4
Amarin Corporation plc
NASDAQ: AMRN
AMRN Trading
-3.74% G/L:
$14.16 Last:
15,657 Volume:
$14.51 Open:
AMRN Latest News
March 18, 2026 08:30:00 am
Amarin Highlights Guideline Recommended Role of Icosapent Ethyl in Managing Cardiovascular Risk Following Release of Updated 2026 ACC/AHA/Multisociety Dyslipidemia Guideline
March 07, 2026 01:35:00 am
Here's Why I Wouldn't Touch Amarin With a 10?Foot Pole Given Its Patent and Competition Risks
AMRN Stock Data
$312,618,004
18,426,477
1.2%
30
N/A
Pharmaceuticals
Healthcare
IE
Dublin 2
